| [1] |
Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33( 10): 1847- 1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003. |
| [2] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69( 2): 406- 460. DOI: 10.1016/j.jhep.2018.03.024. |
| [3] |
RUNYON BA, AASLD PRACTICE GUIDELINES COMMITTEE. Management of adult patients with ascites due to cirrhosis: An update[J]. Hepatology, 2009, 49( 6): 2087- 2107. DOI: 10.1002/hep.22853. |
| [4] |
CHINA L, FREEMANTLE N, FORREST E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis[J]. N Engl J Med, 2021, 384( 9): 808- 817. DOI: 10.1056/nejmoa2022166. |
| [5] |
CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis(ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391( 10138): 2417- 2429. DOI: 10.1016/S0140-6736(18)30840-7. |
| [6] |
FERNÁNDEZ J, CLÀRIA J, AMORÓS A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis[J]. Gastroenterology, 2019, 157( 1): 149- 162. DOI: 10.1053/j.gastro.2019.03.021. |
| [7] |
THÉVENOT T, BUREAU C, OBERTI F, et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial[J]. J Hepatol, 2015, 62( 4): 822- 830. DOI: 10.1016/j.jhep.2014.11.017. |
| [8] |
Harmonised Tripartite Guideline ICH. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group[J]. Stat Med, 1999, 18( 15): 1905- 1942.
|
| [9] |
Committee for Medicinal Products for Human Use(CHMP). Guideline on the choice of the non-inferiority margin[M]. London: European Medicines Agency, 2005.
|
| [10] |
GOULD AL. Sample size re-estimation: Recent developments and practical considerations[J]. Stat Med, 2001, 20( 17-18): 2625- 2643. DOI: 10.1002/sim.733. |
| [11] |
PROSCHAN MA, HUNSBERGER SA. Designed extension of studies based on conditional power[J]. Biometrics, 1995, 51( 4): 1315- 1324.
|
| [12] |
MEHTA CR, POCOCK SJ. Adaptive increase in sample size when interim results are promising: A practical guide with examples[J]. Stat Med, 2011, 30( 28): 3267- 3284. DOI: 10.1002/sim.4102. |
| [13] |
FRIEDE T, KIESER M. Sample size recalculation in internal pilot study designs: A review[J]. Biom J, 2006, 48( 4): 537- 555. DOI: 10.1002/bimj.200510238. |
| [14] |
SCHUMI J, WITTES JT. Through the looking glass: understanding non-inferiority[J]. Trials, 2011, 12: 106. DOI: 10.1186/1745-6215-12-106. |
| [15] |
SNAPINN SM. Noninferiority trials[J]. Curr Control Trials Cardiovasc Med, 2000, 1( 1): 19- 21. DOI: 10.1186/cvm-1-1-019. |
| [16] |
DENNE JS. Sample size recalculation using conditional power[J]. Stat Med, 2001, 20( 17-18): 2645- 2660. DOI: 10.1002/sim.734. |
| [17] |
JOSHUA CHEN YH, DEMETS DL, GORDON LAN KK. Increasing the sample size when the unblinded interim result is promising[J]. Stat Med, 2004, 23( 7): 1023- 1038. DOI: 10.1002/sim.1688. |
| [18] |
CUI L, HUNG HM, WANG SJ. Modification of sample size in group sequential clinical trials[J]. Biometrics, 1999, 55( 3): 853- 857. DOI: 10.1111/j.0006-341x.1999.00853.x. |
DownLoad: